A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Condition:   Advanced or Metastatic Solid Tumors
Interventions:   Drug: ABBV-368;   Drug: Nivolumab
Sponsor:   AbbVie
Not yet recruiting - verified February 2017

http://ift.tt/2lAs7JH